uniQure N.V. Depreciation
uniQure N.V. (QURE) reported Depreciation of $9.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-02
- uniQure N.V. depreciation for the quarter ending 2018-12-31 was $1.80M, a 5.26% decline year-over-year.
- uniQure N.V. depreciation for the quarter ending 2018-09-30 was $1.70M, a 0.00% change year-over-year.
- uniQure N.V. depreciation for the quarter ending 2018-06-30 was $1.50M, a 11.76% decline year-over-year.
- uniQure N.V. depreciation for the quarter ending 2018-03-31 was $1.50M, a 11.76% decline year-over-year.
- uniQure N.V. depreciation for fiscal 2025 was $9.10M, a 9.90% decline from fiscal 2024.
- uniQure N.V. depreciation for fiscal 2024 was $10.10M, a 1.94% decline from fiscal 2023.
- uniQure N.V. depreciation for fiscal 2023 was $10.30M, a 25.61% increase from fiscal 2022.
- uniQure N.V. depreciation for fiscal 2022 was $8.20M, a 34.43% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $9.10M 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $10.10M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $10.30M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $8.20M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $6.10M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $5.70M 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $6.00M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.50M derived: sum of 2 quarters · filed 2021-03-01 | $5.00M derived: sum of 3 quarters · filed 2021-03-01 | $6.50M 10-K · filed 2021-03-01 |
| 2018-09-30 | $1.70M 10-Q · filed 2018-11-06 | $3.20M derived: sum of 2 quarters · filed 2018-11-06 | $4.70M 10-Q · filed 2018-11-06 | $6.60M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.50M 10-Q · filed 2018-08-08 | $3.00M 10-Q · filed 2018-08-08 | $4.90M derived: sum of 3 quarters · filed 2020-03-02 | $6.60M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $1.50M 10-Q · filed 2018-04-30 | $3.40M derived: sum of 2 quarters · filed 2020-03-02 | $5.10M derived: sum of 3 quarters · filed 2020-03-02 | $6.80M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $3.60M derived: sum of 2 quarters · filed 2020-03-02 | $5.30M derived: sum of 3 quarters · filed 2020-03-02 | $7.00M 10-K · filed 2020-03-02 |
| 2017-09-30 | $1.70M 10-Q · filed 2018-11-06 | $3.40M derived: sum of 2 quarters · filed 2018-11-06 | $5.10M 10-Q · filed 2018-11-06 | $6.50M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $1.70M 10-Q · filed 2018-08-08 | $3.40M 10-Q · filed 2018-08-08 | $4.80M derived: sum of 3 quarters · filed 2019-02-28 | $6.20M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $1.70M 10-Q · filed 2018-04-30 | $3.10M derived: sum of 2 quarters · filed 2019-02-28 | $4.50M derived: sum of 3 quarters · filed 2019-02-28 | $5.80M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $2.80M derived: sum of 2 quarters · filed 2019-02-28 | $4.10M derived: sum of 3 quarters · filed 2019-02-28 | $5.50M 10-K · filed 2019-02-28 |
| 2016-09-30 | $1.40M 10-Q · filed 2017-11-01 | $2.70M derived: sum of 2 quarters · filed 2017-11-01 | $4.10M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $1.30M 10-Q · filed 2017-08-08 | $2.70M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $1.40M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $4.40M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $2.00M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |